SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Uniting the six native Japanese dog breeds. Kendu is the keeper of peace, the preserver of life, and the protector of unity. Join the pack!!

Kendu

Kendu is generating intense community engagement as holders focus on its identity as a permissionless brand that incentivizes real-world product development and grassroots marketing. Supporters are actively showcasing their conviction by organizing in-person events and launching diverse initiatives, positioning the project as a long-term, community-driven play.

iShares Inc. - iShares MSCI Japan ETF

iShares MSCI Japan ETF

The iShares MSCI Japan ETF is drawing attention as investors navigate the impact of evolving Bank of Japan policies on the yen and broader equity valuations. Market participants are actively discussing the potential for a long-term shift in the Japanese economy, with mixed sentiment regarding whether ongoing stimulus or interest rate adjustments will fuel further growth or volatility.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is capturing attention as traders debate its long-term potential as a high-performance Layer-1 chain while navigating recent price volatility and staking reward opportunities. Community sentiment remains polarized, with many users actively accumulating and staking to leverage high yields while others express frustration over recent price declines.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following a massive surge in March delivery numbers that significantly beat growth expectations, fueling strong community excitement for potential profitability. Investors are actively discussing the company's multi-brand expansion and the potential for a short squeeze as the stock continues to test key resistance levels.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is seeing increased market attention driven by its recent integration into post-quantum cryptographic standards and ongoing discussions regarding its status as a digital commodity rather than a security. Community sentiment remains polarized, with active debates centered on long-term institutional adoption potential, concerns over foundation governance, and the opportunity for accumulation amidst ongoing price volatility.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is capturing attention as investors weigh its potential for future integration with major platforms against a volatile market backdrop. While some community members remain bullish, citing long-term holding strategies and upcoming utility catalysts, others are actively debating whether current support levels will hold or if a deeper correction is imminent.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class C

Alphabet is trending as investors debate the impact of newly revealed memory-compression technology on the broader semiconductor sector, while community discussions intensify around the company's long-term AI strategy and its diverse portfolio, including stakes in major firms like SpaceX and Anthropic.

Amprius Technologies, Inc. engages in the development, manufacture, and market of lithium-ion batteries for mobility applications, including the aviation, electric vehicle and light electric vehicle industries. It operates through the following geographical segments: North America, EMEA, and Asia Pacific. The company was founded by Mark C. Platshon in 2008 and headquartered in Fremont, CA.

Amprius Technologies Inc

Amprius Technologies is trending as investors react to strong quarterly earnings, where the company reported significant year-over-year revenue growth and increased its 2026 revenue guidance. The community is actively discussing the company's expanding customer base and potential for long-term growth as a key battery supplier within the drone and defense sectors, while also debating the stock's volatility and the impact of upcoming warrant triggers.

iShares Trust - iShares Russell 2000 ETF

iShares Russell 2000 ETF

The iShares Russell 2000 ETF (IWM) is facing significant downward pressure as market participants react to the ongoing volatility and geopolitical uncertainty surrounding the conflict in Iran. Community discussions are heavily centered on hedging against potential further downside, with traders closely monitoring technical support levels and high put option volume as they debate whether the small-cap sector will face a deeper correction or find a bottom in the coming weeks.

Abacus Global Management, Inc. is a pioneering alternative asset manager specializing in uncorrelated financial products that leverage proprietary longevity data and actuarial technology. It operates through the following business segments: Asset Management, Life Solutions and Technology Services. The Asset Management segment provides asset management services primarily to institutional investors, as well as private clients, investing in uncorrelated longevity-based assets, fixed-income replacement strategies, and free cash flow–based investment solutions. The Life Solutions segment is engaged in the buying, selling, and trading of policies, as well as maintaining policies until the receipt of death benefits. The Technology Services segment provides real-time mortality verification, missing participant verification, and other life insurance–specific services to customers on a contract basis. The company was founded by Matthew Ganovsky, Kevin Scott Kirby, and Todd Sean McNealy in 2004 and is headquartered in Orlando, FL.

Abacus Global Management Inc. - Ordinary Shares - Class A

Abacus Global Management is capturing investor attention as its vertical integration strategy, highlighted by a major strategic stake in Manning & Napier, signals a push to control both the origination and distribution of wealth and insurance solutions. While the stock has seen significant momentum, community discussion is currently polarized between those bullish on the company's record growth and platform scalability and those concerned by recent price volatility and technical trading pressures.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Medical Device Innovator Lands Strategic Partner to Accelerate U.S. Expansion

As healthcare systems continue shifting toward outpatient care and at-home recovery, demand is rising for technologies that improve patient outcomes beyond the hospital setting. From post-surgical recovery to vascular health management, providers are increasingly prioritizing mobile, patient-compliant solutions that can extend care into everyday environments.Shares of Therma Bright Inc. (TSX-V: THRM) (OTCQB: TBRIF) are in focus Tuesday after the company announced a new strategic commercial partnership with Horizon Health, a U.S.-based provider of durable medical equipment with deep ties to ...

Therma Bright, Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX), a burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:<ol><li>Managing symptoms of post-thrombotic syndrome (PTS)</li><li>Preventing primary thrombosis</li><li>Treating lymphedema</li><li>Reducing post-operative pain and swelling</li><li>Alleviating leg swelling caused by vascular insufficiency</li><li>Treating varicose veins</li><li>Managing chronic venous insufficiency</li><li>Enhancing blood circulation</li><li>Addressing intermittent claudication</li></ol>All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

Therma Bright (TBRIF) Stock Skyrockets After Medicare and Medicaid Milestone, Enters Multi-Billion-Dollar Market

Therma Bright’s Venowave VW5 achieves a Medicare code, boosting its market reach in DVT treatment. With new partnerships and a diverse product pipeline, the company is set for significant growth.

Therma Bright Gains Medicare Milestone, Expands into $1.5B Market

public companies

Therma Bright’s stock surges as its Venowave VW5 device secures a crucial Medicare and Medicaid designation, entering the $1.5B DVT market. With a strategic distribution partnership, Therma Bright is poised for rapid growth in medical devices and therapies.


Click to follow <a href="https://stocktwits.com/symbol/TBRIF">Therma Bright, Inc. </a>(TSXV: THRM) (<a href="https://stocktwits.com/symbol/TBRIF">OTCQB: TBRIF</a>) (FSE: JNX)A burgeoning name in the medical device industry, has achieved a significant breakthrough for its flagship product, the Venowave VW5. This circulation-enhancing device recently secured a crucial designation from the Centers for Medicare and Medicaid Services (CMS), positioning it for success within the expansive Medicare and Medicaid frameworks.The Venowave VW5 has been awarded a permanent Healthcare Common Procedure Coding System (HCPCS) code, a pivotal development that could propel Therma Bright into the forefront of the deep vein thrombosis (DVT) treatment market. Industry estimates project this market to grow to $1.5 billion by 2032, offering substantial growth prospects for Therma Bright, which currently holds a modest market cap of USD $21 million.Introducing Therma Bright: Innovating Blood Clot Prevention, and BeyondTherma Bright, Inc., the innovative force behind the Venowave VW5, specializes in cutting-edge diagnostic and medical device technologies. While the company boasts a diverse portfolio, the Venowave VW5 is currently generating the most investor enthusiasm.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_14_31_PM_5254def16f.png" alt="Screenshot 2024-09-10 at 5.14.31 PM.png">The Venowave VW5 is a device designed to be worn on the calf, where it generates wave-like motions to massage the leg and promote blood circulation. This function is critical in pushing blood back to the heart, helping to prevent blood clotting, particularly in cases of DVT—a condition that affects approximately 900,000 Americans annually, according to the CDC. Unlike traditional compression socks, which can cause discomfort and skin issues, the VW5 offers a more comfortable and effective alternative for DVT patients.Venowave VW5 Achieves Key Medicare &amp; Medicaid DesignationThe Venowave VW5 is the first device of its kind to be classified as Durable Medical Equipment (DME) with a new HCPCS Level II code. This designation enhances the device's credibility as a treatment option and streamlines billing and reimbursement processes through Medicare and Medicaid. This is expected to increase its appeal among patients seeking treatment for DVT.Medicare and Medicaid reimbursement is crucial for a company like Therma Bright because it opens the door to a vast and stable market of insured patients, ensuring consistent demand for their products. Securing reimbursement from these programs not only validates the effectiveness and necessity of their devices but also simplifies the purchasing process for patients and healthcare providers. For investors, this is a significant milestone as it enhances the company’s revenue potential and reduces financial risk, making Therma Bright a more attractive and reliable investment opportunity.As per the recent announcement, patients will have the option to purchase a pair of Venowave devices outright with a capped reimbursement of $1,199. Alternatively, they can opt for a rental plan, with monthly reimbursement capped at $78.05, totaling $819.55 over 13 months. Ownership of the device will transfer to the patient after the 13th rental payment.Strategic Distribution Partnership SecuredShortly after receiving its new designation, Therma Bright announced a partnership with a major distributor to launch an initial sales program. This initiative aims to assess Medicare and Medicaid reimbursement timelines and billing procedures. If successful, the distributor has agreed to purchase the remaining Venowave VW5 inventory, valued at $2.38 million.While the distributor's identity has not been disclosed, it is expected that further details will emerge as the program progresses. This partnership marks a crucial step towards establishing the VW5 as a preferred DVT treatment, particularly for patients covered by Medicare and Medicaid. Therma Bright's CEO, Rob Fia, anticipates a "significant increase" in monthly orders as a result.Beyond DVT: Expanding the Venowave VW5's ApplicationsWhile the Venowave VW5 is already gaining attention for its role in DVT treatment, its potential applications extend far beyond. The device is capable of addressing a wide range of conditions, significantly broadening Therma Bright's total addressable market.In addition to DVT, the VW5 can be used for:- Managing symptoms of post-thrombotic syndrome (PTS)- Preventing primary thrombosis- Treating lymphedema- Reducing post-operative pain and swelling- Alleviating leg swelling caused by vascular insufficiency- Treating varicose veins- Managing chronic venous insufficiency- Enhancing blood circulation- Addressing intermittent claudication&nbsp;All of these ailments represent blue sky for Therma Bright as each one of these very common medical issues, as they potentially become approved, would unlock a whole new category of customer for the company.&nbsp;Therma Bright's Diverse, Late-Stage Product Pipeline&nbsp;Therma Bright's diverse product portfolio is a key driver of its investor appeal, with its investment in Inretio at the forefront.&nbsp;Inretio is revolutionizing ischemic stroke treatment with its Preva® clot-retrieval device, which has recently completed its<a href="https://finance.yahoo.com/news/therma-bright-major-milestone-portfolio-100000110.html"> third successful human trial</a>. This groundbreaking technology represents a significant leap in thrombectomy procedures, offering unmatched precision in restoring blood flow for stroke patients, even when traditional treatments like tPA fail.&nbsp;<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_28_PM_5b99c7f619.png" alt="Screenshot 2024-09-10 at 5.15.28 PM.png">The Preva® device's patented protective basket design reduces the risk of embolization and minimizes the need for repeated maneuvers, positioning it as a potential game-changer in the global market for advanced clot removal solutions. As Inretio progresses towards FDA 510K designation, the success of the Preva® device underscores the strategic value of Therma Bright's investment in cutting-edge medical technologies.With the global coronary stents market expected to reach $4.8 billion by 2029, the continued development of this device could greatly enhance Therma Bright's portfolio.The $16 Billion COPD MarketTherma Bright is making significant strides with its investment in InStatin, a company developing innovative inhaled statin therapies for respiratory diseases like asthma and Chronic Obstructive Pulmonary Disease (COPD). Unlike traditional statin therapies that are administered orally, InStatin’s novel delivery system targets the airways and lungs directly, potentially offering a more effective treatment at lower dosages. This cutting-edge approach could revolutionize the management of these respiratory conditions, which collectively affect over 600 million people globally.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_34_PM_afe9034042.png" alt="Screenshot 2024-09-10 at 5.15.34 PM.png">The global market for asthma and COPD treatments is substantial, with an estimated value exceeding $16 billion annually. This presents a significant growth opportunity for Therma Bright as InStatin progresses through pre-clinical stages. The unique benefits of inhaled statins—such as reduced tissue thinning and longer-lasting therapeutic effects compared to steroids—position this technology as a promising alternative in a market that has seen little innovation over the past 50 years.With a 17% equity stake in InStatin and a 60% stake in Invixa, Therma Bright is well-positioned to capitalize on the success of these therapies.Turn Your Head and CoughTherma Bright has also played a pivotal role in developing the Digital Cough Test in collaboration with AI4LYF. This innovative app uses artificial intelligence to monitor various respiratory diseases through cough analysis, further diversifying Therma Bright’s product offerings.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_09_10_at_5_15_39_PM_68fe2a4028.png" alt="Screenshot 2024-09-10 at 5.15.39 PM.png">Bringing it all TogetherTherma Bright's strategic focus on both medical devices and drug therapies places the company in a unique position within the healthcare sector. The company’s flagship products—ranging from the Venowave VW5 for DVT prevention to the Preva® clot-retrieval device and inhaled statin therapies—target significant, multi-billion-dollar markets. Combined, the market opportunities across these indications surpass $22 billion globally, highlighting the substantial revenue potential for Therma Bright which pales in comparison to their tiny market value of just USD $21 Million.What sets Therma Bright apart is its emphasis on medical devices, which typically face shorter, less expensive, and less risky development timelines compared to pharmaceutical drugs. The company's advancements with the Venowave VW5 and Preva® device, both of which are already far along in the regulatory process, partially de-risk their pipeline. This progress contrasts with the longer, more expensive, and more uncertain path often associated with drug development.&nbsp;By focusing on innovative medical devices that address large and unmet medical needs, Therma Bright is poised to potentially capture significant market share, offering a compelling growth story for investors as it continues to push the boundaries of healthcare innovation.

<h1>Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market</h1><h2>Therma Bright (THRM) secures permanent Medicare and Medicaid reimbursement codes for Venowave VW5, making it the only product with reimbursement codes in deep vein thrombosis (DVT) market, expected to grow in value to US $1.55 billion by 2032.</h2>&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/tag/therma-bright">Therma Bright (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX)</a>, a leader in proprietary diagnostic and medical device technology, is making significant strides in addressing critical health challenges with its innovative solutions. The company’s&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">latest achievement</a>, the permanent Healthcare Common Procedure Coding System (HCPCS) code E0683 for its Venowave VW5 device, marks a crucial milestone in enhancing patient care and expanding market reach.<h3>Venowave VW5: A Revolutionary Approach to Circulatory Health</h3>The&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/venowave/">Venowave VW5</a> is a first-of-its-kind piece of Durable Medical Equipment designed to treat and prevent deep vein thrombosis (DVT) and other circulatory issues by utilizing a series of compact, battery-operated peristaltic pumps that generate a wave-form motion.Worn below the knee and strapped firmly to the calf, the Venowave device provides compression to the calf and creates an increased upward volumetric displacement of venous and lymph fluid, resulting in improved vascular and lymphatic flow in the lower limbs.The device, now recognized by the U.S. Department of Health &amp; Human Services’ Centers for Medicare and Medicaid Services (CMS) with its own HCPCS code, offers patients a much-needed alternative to traditional treatments like compression socks. Unlike compression socks, which can cause discomfort and skin issues, the Venowave VW5 uses its wave-form motion to gently massage the calf, improving blood circulation without the associated drawbacks.Rob Fia, CEO of Therma Bright, commented on the milestone announcement, stating:<blockquote>“We’re pleased that the Centers for Medicare and Medicaid has approved our permanent code request, as well as the reimbursement pricing and the new HCPCS Level II designation for our Venowave VW5 device. As shared in several of our recent press announcements, the CDC estimates that over 900,000 U.S. citizens suffer from deep vein thrombosis (DVT) and MarketDigit’s research projected this disease will ‘reach USD 1.5 Billion by 2032’ on a global market value perspective. And DVT is only one medical condition area out of ten circulatory issues that the permanent code will cover, which is very exciting.”</blockquote>The reimbursable codes are not only a great opportunity for Therma Bright but also for the company’s customers, reseller partners and shareholders.The Medicare and Medicaid codes for the Venowave VW5 cover the following ten indications:– Prevention of deep vein thrombosis (DVT) – Management of the symptoms of post-thrombotic syndrome (PTS) – Prevention of primary thrombosis – Treatment of lymphedema – Diminishing post-operative pain and swelling – Treatment of leg swelling due to vascular insufficiency – Treatment of varicose veins – Treatment of chronic venous insufficiency – Enhancing blood circulation – Treatment of intermittent claudicationPer this morning’s Therma Bright&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220400/Therma-Brights-Venowave-VW5-Secures-Permanent-HCPCS-Code-E0683-from-U.S.-DHHSs-Centers-for-Medicare-Medicaid-Services?k=therma%20bright">press release</a>, the Venowave VW5 will have a complete patient buyout option for a pair of Venowave devices with a capped reimbursement of $1,199.The Venowave VW5 can also be rented with a capped rental fee reimbursement of $78.05 per month. The total capped rental reimbursement payment for 13 months of continuous use is $819.55, and following the 13th rental payment, the patient will become the owner of the Venowave VW5.The device’s impact is underscored by the growing need for effective DVT treatments. The global market for DVT prevention is&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/en/news-release/2024/01/29/2819535/28124/en/Deep-Vein-Thrombosis-Market-Projected-to-Ascend-to-1-26-billion-by-2028-A-Fresh-Global-Market-Report-Unveiled.html">projected to grow</a> steadily at a CAGR of 4.1% and reach US $1.26 billion by 2028 and US $1.55 billion by 2032, driven by an aging population and the increasing prevalence of lifestyle diseases like obesity. With over 900,000 Americans affected by DVT annually, the Venowave VW5 is poised to play a critical role in managing and preventing this life-threatening condition.Highlighting the significance of the development, Fia added:<blockquote>“This innovative device for addressing DVT and these other blood circulation issues is the first-of-its-kind to receive the permanent HCPCS Level II code, and we look to provide an initial sales update on our solution in the coming week. One key competitive product in the marketplace is the compression sock, which applies controlled and constant pressure on the leg to improve blood flow in the veins. Unfortunately, users of the compression socks can experience a variety of challenges, including difficulty in putting the sock on, discomfort from constant pressure, minor bruising, skin ulcers, dry skin, redness, and itching. In contrast, the Venowave VW5 simply straps on and massages the leg, applying appropriate pressure in a comfortable and soothing manner to circulate blood through the veins.”</blockquote><h3>Expanding the Portfolio: AI-Powered Solutions and Strategic Investments</h3><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/">Therma Bright</a>‘s commitment to innovation extends beyond the Venowave VW5. The company is also at the forefront of integrating artificial intelligence (AI) into healthcare, as demonstrated by its Digital Cough Technology (DCT). Developed in partnership with&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.thermabright.com/ai4lyf/">AI4LYF</a>, this AI-powered platform is currently&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.newsfilecorp.com/release/220173/Therma-Brights-AIPowered-Digital-Cough-Technology-Being-Considered-as-Partner-Technology-in-New-Chronic-Cough-Drug-Clinical-Trial">under consideration</a> for a U.S. clinical trial involving a new chronic cough drug. The DCT platform enables healthcare providers and epidemiologists to make more accurate and informed decisions by analyzing cough sounds, thereby improving the diagnosis and management of respiratory conditions.Fia explained:<blockquote>“Our DCT solution and data collection platform is ideally positioned for clinical studies like this one. It allows health practitioners to quickly address a patient’s respiratory issues, ultimately leading to better health outcomes.”</blockquote>Therma Bright’s strategic investments further solidify its position in the medical device industry. The company’s portfolio includes a stake in Inretio, which is revolutionizing ischemic stroke treatment with its innovative clot-retrieving device, PREVATM. This technology has shown promising results in early trials, achieving an 80% success rate compared to the 50% effectiveness of existing devices. Additionally, Therma Bright is developing inhaled statin therapies for asthma and COPD, offering a new approach to treating these widespread respiratory conditions.<h3>The Road Ahead: A Focus on Patient-Centered Innovation</h3>Therma Bright’s focus on patient-centred innovation is evident in its approach to product development and market expansion. The company’s Venowave VW5 not only provides a new standard in DVT treatment but also sets the stage for further advancements in circulatory and respiratory health.As the healthcare landscape continues to evolve, Therma Bright is well-positioned to lead the way with its cutting-edge technologies. With the Venowave VW5 already making waves in the market and its AI-powered DCT platform on the brink of clinical integration, the company is poised to make a lasting impact on the health and well-being of millions.<h3>Therma Bright (TSXV: THRM) Stock Price Action</h3>Shares of Therma Bright stock are in the midst of an epic breakout, with THRM stock up as much as&nbsp;350% since July 31, 2024, and as much as&nbsp;800% since May 31, 2024.Therma Bright stock last traded at $0.085. YTD, THRM stock is up&nbsp;183.33%.<img src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_08_20_at_7_52_22_PM_ae153f1a0d.png" alt="Screenshot 2024-08-20 at 7.52.22 PM.png" width="1436" height="864">Therma Bright, (TSXV: THRM), six-month interactive stock chart. (Source: Barchart)<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.barchart.com/stocks/quotes/THRM.VN/interactive-chart">View Therma Bright Stock Chart on Barchart</a>Read Next:&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://wealthyvc.com/biotech/tempest-therapeutics-tpst-stock-jumps-83-on-fda-phase-3-trial-news/">Tempest Therapeutics (TPST) Stock Jumps 83% on FDA Phase 3 Trial News</a><a target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/groups/WealthyVC">Join the Discussion in the WVC Facebook Investor Group</a>Have a Stock Tip or New&nbsp; Story Suggestion? Email us at&nbsp;Invest@WealthyVC.comTherma Bright Inc. (CSE: PAID) is a paid client of Wealthy VC. This report/release/profile is a commercial advertisement and is for general information purposes only.&nbsp;&nbsp;This article was written by an independent contributor and does not reflect the views of Stocktwits. It has not been edited for content. The information provided here is intended solely for informational and educational purposes, and should not be interpreted as investment advice. Stocktwits does not endorse the purchase or sale of any security nor does it make any claims about the financial status of any company.

Tiny Healthcare Stock With $35 Million Market Cap Becomes Major Player Overnight in Rapidly Growing $1 Billion Market

Therma Bright secures Medicare codes for its Venowave VW5, boosting its market presence in the $1.5B DVT market and driving an 800% stock surge since May 2024.

Therma Bright Gains Medicare Code for Venowave, Stock Soars

Equity

Therma Bright (TSXV: THRM) secures permanent Medicare and Medicaid reimbursement codes for its Venowave VW5 device, making it the only DVT treatment with such codes. This innovation has driven significant stock gains, with shares rising over 800% since May 2024.

Therma Bright, Inc. engages in developing and marketing skin care medical device products. Its products include Therapik, which is used to relieve the pain, itch and inflammation of stings and bites from different species of insects and InterceptCS, which is a device to prevent cold sore outbreaks. The company was founded in 2001 and is headquartered in Toronto, Canada.

Therma Bright Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

TBRIF
Therma Bright Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest TBRIF News

TBRIFTherma Bright Inc